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Abstract
Background: Formation of cellular malignancy results from the disruption of fine tuned signaling homeostasis for
proliferation, accompanied by mal-functional signals for differentiation, cell cycle and apoptosis. We wanted to
observe central signaling characteristics on a global view of malignant cells which have evolved to selfishness and
independence in comparison to their non-malignant counterparts that fulfill well defined tasks in their sample.
Results: We investigated the regulation of signaling networks with twenty microarray datasets from eleven
different tumor types and their corresponding non-malignant tissue samples. Proteins were represented by their
coding genes and regulatory distances were defined by correlating the gene-regulation between neighboring
proteins in the network (high correlation = small distance). In cancer cells we observed shorter pathways, larger
extension of the networks, a lower signaling frequency of central proteins and links and a higher information
content of the network. Proteins of high signaling frequency were enriched with cancer mutations. These proteins
showed motifs of regulatory integration in normal cells which was disrupted in tumor cells.
Conclusion: Our global analysis revealed a distinct formation of signaling-regulation in cancer cells when
compared to cells of normal samples. From these cancer-specific regulation patterns novel signaling motifs are
proposed.
Background
Endogenous signal transduction in cancer cells is system-
atically disturbed to redirect the cellular decisions from
differentiation and apoptosis to proliferation and, later,
invasion [1]. Cancer cells acquire their malignancy
through accumulation of advantageous gene mutations
by which the necessary steps to malignancy are obtained
[2]. These selfish adaptations to independence can be
described as a result from an evolutionary process of
diversity and selection [3]. We were interested to observe
the resulting cellular signal transduction on a global
view. Experimental high throughput methods such as
gene expression profiling with microarrays enable investi-
gating the pathogenic function of tumors on a meso-
scopic level. Large-scale gene expression profiles were
successfully used to predict clinical outcome [4,5] and
improved risk estimation [6]. However these studies
didn’t relate genes and their expression to a functional
context. To gain an understanding on a systems view,
gene expression can be mapped onto cellular networks.
Several studies have been reported that used gene expres-
sion data from microarrays to describe specific character-
istics of signaling networks in cancer. Discriminative
components of a protein-protein interaction network
were identified by comparing gene expression patterns of
metastatic and non-metastatic tumors in breast cancer
and suited as risk markers for metastasis of breast cancer
[7]. New genetic mediators for prostate cancer were
found with networks that were reversely engineered from
gene expression profiles [8]. Besides this, insights into
evolutionary principles were gained by the analysis of
gene expression profiles. Gene expression differences
were used to define phylogenetic relationships of several
Drosophila species [9] and a molecular clock for primates
[10]. Furthermore, the regulation of signaling in yeast
was investigated on a global scale to observe regulatory
adaptation to the cellular environment. Yeast responded
to exogenous signals by shorter regulatory cascades to
enable fast signal propagation [11].
The aim of our work was to detect characteristic sig-
naling properties of cancer cells on a global scale. We
compared the regulation of signaling pathways in cancer
with normal cells and mapped gene expression data of
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tumors and their corresponding non-malignant ("nor-
mal”) samples onto a comprehensive protein-protein-
interaction network. For inferring regulation-principles
in cellular signal transduction, we used a graph search-
ing algorithm that tracked pathways with the highest
correlation in regulation. We investigated twenty tumor-
datasets comprising acute myeloid leukemia, esophageal
squamos cell-, lung adeno- and renal clear cell carci-
noma, breast-, cervical-, head-and-neck-, oral-tongue-,
pancreas- and prostate cancer, and vulva interstitial
neoplasia. The investigated tumors showed shorter path-
ways, but a larger extension of the network. The tumors
displayed lower frequency of central proteins and links
and a higher information entropy (Shannon’s informa-
tion content) in their network. These findings were
embedded into a novel signal-regulation motif which
was observed considerably more often in normal cells
when compared to tumor cells (Figure 1). Similar to the
study of Cui and co-workers [12], central proteins
(hubs) were enriched with cancer mutations. We
observed that these proteins showed higher regulation-
integrity in the normal samples whereas the tumor sam-
ples showed motifs of regulatory maintenance of the
neighbors of hubs.
Results
Constructing the signaling networks
We assembled our signaling network employing a com-
prehensive data repository of known protein-protein
interactions from the literature (HPRD: Human Protein
Reference Database [13,14] version 9 from April 13th,
2010). Proteins were represented by their coding genes
and will also be denoted as nodes of the networks in the
following. Gene expression data of each cancer dataset
(malignant cells) and the corresponding set of normal
samples (non-malignant cells) was mapped onto the
nodes of the network. Depending on the coverage of the
probes on the microarray chips, the intersection with
the HPRD network comprised of 5574 to 8651 nodes
including 559 to 706 receptors and 505 to 617 transcrip-
tion factors (Table 1). Similar to Luscombe and co-
workers, we assumed most likely signaling propagation
by high co-regulation of genes of two neighboring
proteins in the network [11]. We calculated protein-
protein-distances for each link (link-distances) by the
co-regulation (one minus the absolute value of Pearson’s
correlation) of the two interacting proteins (Additional
file 1: Supplemental Figure S1). The link-distances were
higher (lower absolute correlation) in cancer cells com-
pared to normal cells (average of average link-distances
in normal: 0.34, and tumor: 0.52, P = 1.53E-05, Table
1). We defined pathways for each pair of receptors (sig-
nal-operator) and transcription-factors (signal-receiver)
by their shortest paths yielding a range of 282,295 to
435,602 pathways for each of the investigated cancer
datasets. The tumor cells showed a distinct higher cov-
erage of the original protein-interaction network for
these pathways. Table 1 gives an overview of the net-
work data for the different datasets we analyzed and
also the network-coverage of all receptor-transcription-
factor pathways for the tumors and the reference sam-
ples. From these pathways we constructed specific net-
works for each tumor and reference sample. For each
tumor and normal sample, the constructed networks
consisted only of those links and nodes that appeared at
least once in their receptor-transcription-factor path-
ways. Not-appearing links and nodes were discarded
(Figure 2 shows the number of nodes in all constructed
networks of normal and cancer tissues). We were inter-
ested if these networks were specific for the respective
tumor type. For this, we extracted all somatically
mutated genes for specific cancer tissues from a data-
base (COSMIC [15]) and tested if our tumor networks
contained genes which have been described specifically
for the respective tumors. We performed enrichment
Figure 1 Comparative cancer motif. Two different signals are
transmitted from two receptors (R1 and R2) to a transcription factor
(TF). Green and grey arrows indicate the pathways for normal and
cancer cells, respectively. The motif was defined for each pair of
pathways (from R1 to TF, and from R2 to TF) such that the
pathways of normal cells share at least one common link whereas
the pathways for cancer cells did not share any link.
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tests (Fisher’s exact tests) and found that all tumor
networks showed a considerably significant enrichment
of their corresponding mutated tumor genes (Additional
file 1: Supplemental Table S1).
Tumors use shorter paths, more links and less hubs
We calculated a variety of different network-features to
characterize specific differences in signaling-regulation
of tumor cells and non-malignant cells. The results are
given in Table 2 and Table 3 and will be explained in
the following. For getting a reasonable estimate of the
general tendency of tumors, we calculated the average
out of all datasets for cancer and normal networks and
performed a significance test of the pair-wise differences
between tumor and normal (paired, non-parametric,
Wilcoxon-rank test).
The average path-length of cancer networks was less
than for non-malignant (average for cancer: 4.58, and
normal: 5.50, P = 3.82E-05). We wanted to know how
often the same links (interactions) were used for differ-
ent signaling pathways. For this, we defined the
frequency of a link (link-frequency) as the number of
receptor-transcription-factor pathways it was involved
in. The average link-frequency was obtained by the
number of links used in each single pathway from each
respective receptor to each transcription factor, divided
by the number of all used links. The average link fre-
quency was higher in normal cells (average of average
link-frequency for cancer: 122.6, and normal: 234.4, P =
1.53E-05). Similarly, the node frequency was calculated
and showed the same tendency (average for cancer:
524.3, and normal: 723.4, P = 2.29E-05). Hence net-
works of normal cells used more often the same central
proteins and interactions for different signaling tasks.
Such a hub-like structure is the central characteristic of
scale free networks [16]. We were interested if the net-
works for cancer and normal samples followed these
characteristics and if there were distribution differences
between them. In deed, the link-frequency distribution
of the networks of both entities followed a power law
(probability to draw a link with frequency f is propor-
tional to f-a and a > 1). In comparison to the networks
Table 1 Network sizes

















normal tumor normal tumor normal tumor
AML 1 29211 7244 653 578 39.1 48.8 55.5 69.7 0.32 0.59
AML 2 23181 5574 559 505 36.4 52.7 48.5 72.9 0.07 0.72
Breast 1 29211 7244 653 578 45.7 46.2 65.7 66.3 0.57 0.59
Breast 2 33722 8651 706 617 39.1 40.1 57.6 59.4 0.47 0.53
Cervical 1 33722 8651 706 617 33.7 43.5 47.4 64.9 0.20 0.52
Cervical 2 29211 7244 653 578 43.2 46.8 61.0 66.6 0.38 0.54
ESCC 29211 7244 653 578 45.6 49.9 65.4 71.5 0.51 0.73
Glioma 33722 8651 706 617 39.1 42.0 56.6 62.6 0.36 0.58
Head and
neck
23181 5574 559 505 45.8 45.7 62.0 62.0 0.38 0.41
Lung 1 23181 5574 559 505 48.7 48.4 67.2 67.8 0.47 0.47
Lung 2 29211 7244 653 578 44.4 45.6 62.6 65.3 0.43 0.48
Oral
tongue 1
23181 5574 559 505 46.5 50.5 63.4 70.0 0.40 0.59
Oral
tongue 2
33722 8651 706 617 40.3 42.9 59.6 63.5 0.39 0.54
Pancreas
1
33722 8651 706 617 33.6 42.7 46.4 63.2 0.26 0.53
Pancreas
2
33722 8651 706 617 33.2 43.4 46.3 64.3 0.25 0.57
Prostate
1
23181 5574 559 505 39.5 41.6 50.0 53.7 0.28 0.34
Prostate
2
33722 8651 706 617 41.0 43.6 60.6 64.9 0.41 0.57
Renal 1 29211 7244 653 578 44.1 44.4 63.9 64.3 0.41 0.42
Renal 2 33722 8651 706 617 29.5 41.2 40.2 61.0 0.07 0.54
Vulva 33722 8651 706 617 38.8 39.2 57.8 58.2 0.34 0.36
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from normal cells, the distributions of tumors showed a
steeper decline. We calculated the exponent a of the
distribution and observed larger exponents for cancer
networks (P = 1.91E-06). (exemplarily, Figure 3 shows
the distributions and the regression function for cervical
cancer 1, the distributions for all datasets are given in
Additional file 1: Supplemental Figure S2). This agrees
with the lower average of their link-frequency. These
distributions also show that proteins of high connectiv-
ity (hubs) in the networks of normal cells are more
abundant (Additional file 1: Supplemental Figure S3
shows some illustrations of networks). The clustering
coefficient has been employed as a measure of connect-
edness of networks [16]. We calculated the clustering
coefficient and obtained lower values for the network of
cancer cells supporting our findings that cancer showed
a tendency for less centralized, less hub-dependent for-
mation (average of cancer: 0.118, and normal: 0.125, P =
4.20E-04). Specifically, the number of nodes with a clus-
tering coefficient greater zero was distinctively higher in
cancer cells (average for cancer: 2208 and normal: 1956,
P = 7.63E-05).
Frequently involved genes are enriched with cancer
mutated genes
Cui and co-workers compiled a selective list of 284 can-
cer mutated genes which were derived from large scale
sequencing and the literature (Supplementary Table S10
in [12]). We compared this list with the 50 most fre-
quently involved nodes (our hubs) of each network and
found significant enrichment for 19 out of 20 normal
and tumor datasets (Additional file 1: Supplemental
Table S2). We then defined gene-lists of cancer mutated
hubs for every cancer by intersecting the hubs of our
network with the list of cancer mutated genes of Cui et
al. (Additional file 1: Supplemental Table S3). Interest-
ingly, most of the genes which showed up in the tumor
networks were also present in the normal networks.
This may indicate that normal cells intrinsically pave
the way for their specific evolvement into malignancy.
Signaling-regulation in cancer is detached at cancer
mutated hubs but maintained in their vicinity
Uri Alon and his co-workers studied occurrences of direc-
tion-motifs in triangles and revealed a large variety of
Figure 2 Network characteristics. Number of nodes and path lengths for normal and tumor networks of all investigated cancer types. The
malignant signaling networks employed a higher number of nodes (average normal: 2973, tumor: 3324, P = 2.3E-03) and were more connected
with smaller paths (average normal: 5.4, tumor: 4.6, P = 9.54E-06).
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Table 2 Statistics of general network features
Number of links Exponent a Link frequency Node frequency Path length Increase of path length
normal tumor normal tumor normal tumor normal tumor normal tumor normal tumor
AML 1 16224 20367 1.24 1.28 200 101 720 461 5.40 4.32 1.67 1.57
AML 2 11245 16896 0.98 1.30 719 82 1256 384 9.02 3.99 2.04 1.55
Breast 1 19188 19357 1.27 1.28 113 108 502 487 4.40 4.32 1.59 1.62
Breast 2 19408 20031 1.22 1.23 147 134 605 573 4.70 4.57 1.65 1.63
Cervical 1 15983 21877 1.12 1.26 330 121 962 537 6.41 4.64 1.65 1.58
Cervical 2 17833 19463 1.23 1.27 152 112 613 500 5.09 4.49 1.54 1.58
ESCC 19107 20887 1.25 1.29 122 89 534 424 4.67 4.06 1.56 1.53
Glioma 19102 21114 1.18 1.27 172 120 673 543 5.23 4.53 1.55 1.56
Head and neck 14365 14364 1.23 1.26 141 136 554 539 5.01 4.87 1.59 1.58
Lung 1 15568 15722 1.24 1.28 116 116 484 489 4.65 4.67 1.62 1.58
Lung 2 18295 19080 1.24 1.25 135 121 563 525 4.80 4.60 1.59 1.54
Oral tongue 1 14698 16223 1.23 1.27 136 94 533 432 4.89 4.31 1.61 1.55
Oral tongue 2 20097 21406 1.22 1.25 163 123 649 534 5.19 4.55 1.62 1.62
Pancreas 1 15661 21307 1.18 1.25 230 123 798 536 5.32 4.55 1.65 1.60
Pancreas 2 15604 21671 1.17 1.25 256 113 841 509 5.54 4.39 1.63 1.59
Prostate 1 11590 12450 1.15 1.19 184 154 672 600 5.25 4.93 1.56 1.58
Prostate 2 20446 21899 1.23 1.27 156 114 615 510 5.01 4.42 1.72 1.62
Renal 1 18660 18791 1.25 1.26 148 144 582 581 4.93 4.95 1.70 1.66
Renal 2 13557 20567 1.02 1.26 702 126 1371 552 8.02 4.52 1.55 1.59
Vulva 19491 19612 1.22 1.22 192 185 700 688 5.39 5.36 1.72 1.73
Tendency for tumor Up Up Down Down Down Down
Significance (P-value) 3.81E-06 1.91E-06 3.81E-06 5.72E-06 5.37E-06 0.021














normal tumor normal tumor normal tumor normal tumor normal tumor normal tumor
AML 1 3.94E+07 1.08E+07 541 27 6 26 0.126 0.113 1924 2344 10.94 12.35
AML 2 3.35E+07 3.35E+06 888 0 0 139 0.142 0.119 1373 1971 10.05 12.22
Breast 1 1.82E+07 1.88E+07 34 55 10 6 0.116 0.115 2234 2244 12.07 12.11
Breast 2 2.62E+07 2.39E+07 272 169 17 15 0.119 0.119 2271 2338 11.98 12.05
Cervical 1 5.04E+07 1.19E+07 614 49 4 52 0.134 0.117 1924 2538 10.89 12.12
Cervical 2 2.57E+07 1.74E+07 170 58 2 17 0.118 0.116 2081 2278 11.71 12.16
ESCC 2.52E+07 1.52E+07 70 8 0 6 0.117 0.112 2236 2435 11.99 12.55
Glioma 3.02E+07 2.28E+07 250 92 3 43 0.118 0.115 2242 2450 11.91 12.20
Head and neck 1.31E+07 1.24E+07 205 143 3 14 0.129 0.123 1712 1700 11.38 11.39
Lung 1 1.42E+07 1.40E+07 83 78 15 18 0.124 0.123 1813 1832 11.82 11.57
Lung 2 2.31E+07 1.88E+07 154 99 8 17 0.117 0.117 2137 2233 11.81 12.05
Oral tongue 1 1.84E+07 9.83E+06 231 68 1 32 0.130 0.121 1768 1912 11.42 12.04
Oral tongue 2 3.06E+07 2.15E+07 144 34 3 30 0.121 0.115 2349 2489 11.76 12.23
Pancreas 1 4.20E+07 1.37E+07 1427 115 5 79 0.123 0.114 1873 2457 11.23 12.21
Pancreas 2 4.60E+07 1.16E+07 1250 81 0 81 0.126 0.112 1866 2504 11.19 12.33
Prostate 1 1.37E+07 8.91E+06 573 398 0 3 0.130 0.126 1407 1485 11.06 11.30
Prostate 2 3.07E+07 2.29E+07 178 56 13 24 0.116 0.117 2357 2541 11.79 12.15
Renal 1 2.25E+07 2.24E+07 105 123 20 29 0.119 0.119 2181 2190 11.70 11.69
Renal 2 5.72E+07 7.05E+06 1227 116 8 116 0.138 0.118 1650 2398 10.56 12.16
Vulva 2.81E+07 2.67E+07 231 308 33 23 0.123 0.123 2299 2295 11.57 11.58
Tendency for tumor Down Down Up Down Up Up
Significance (P-value) 9.54E-06 5.53E-04 6.34E-04 1.05E-04 1.91E-05 8.20E-05
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substantial characteristics in signaling networks character-
ized by consistent and non-consistent feed-forward and
feedback loops [16]. We were interested in local regulation
patterns of the networks at cancer mutated hubs. For this,
we analyzed regulation motifs of every triangle consisting
of exactly one hub and two of its neighbors which on their
part also interact. We defined two regulation motifs. The
first motif reflected the degree of regulatory integration of
a hub and its network-vicinity and was defined by a high
correlation of all pairs of nodes in the triangle motif (inte-
grated motif, motif A in Figure 4). We found this motif
significantly more often in normal cells (P = 1.7E-03,
Table 3). The second motif (maintenance motif, motif B in
Figure 4) described triangles which pairs of hub-nodes
(hub-n1, hub-n2) showed high correlation in one tissue
type and no correlation in the other, while the mutual cor-
relation of nodes n1-n2 stayed in the same category (no,
low and high correlation). Such a scenario is reasonable
for a mutated cancer protein with loss-of-function leaving
their neighbors unaffected. Indeed, this motif occurred
more often in the cancer networks (P = 6.34E-04, Table 3).
Tumor networks are more robust against directed attacks
Albert and co-workers showed that scale free networks
are error tolerant only against attacks of randomly
selected nodes but not against directed removals of
central nodes (hubs) [17]. We were interested in the
robustness of the networks when removing their hubs.
For this, we removed the most frequently involved
nodes of every network and calculated the average of
pair-wise distances (average network diameter) as an
estimate of the fragility of the networks [17]. The rela-
tive increase of the network diameter due to the
removal was distinctively larger in normal cells com-
pared to cancer cells (average for cancer: 1.59, average
for normal: 1.64, P = 0.021, Table 2) indicating higher
robustness of the tumor networks against directed
attacks at their hubs.
Lower information content in normal cells
We used the number of pathways each single link was
involved in (link-frequency) as an estimate of the prob-
ability that information (such as a phosphorylation) was
passed through this link. In this simplified model, every
pathway was treated equally. With this, we calculated
the information content for each network. As a measure
of disorder, Shannon’s information entropy [18] was cal-
culated for each network. The cancer networks exhib-
ited a higher information entropy (average for cancer:
11.98, average for normal: 11.38, P = 3.28-04, Table 3)
indicating their higher degree of dispersal.
A comparative network motif
Inspired by the results described above, we designed a
comparative network-motif which is illustrated in Figure 1.
We wanted to put up a model in which cancer cells
use different pathways for different tasks whereas normal
cells use common signaling interactions for different
tasks. Therefore a model was designed such that two path-
ways (two operator-receiver pairs, R1 - TF and R2 - TF in
Figure 1) of the normal tissue shared at least one common
Figure 3 Link frequency distribution. The frequency distribution
of the links for the network of cervical cancer one (red circles) is
shown, in comparison to the distribution of the corresponding
normal network (blue crosses). Both networks (tumor and normal)
showed typical scale-free distributions. In comparison to the
network for normal samples, the cancer network had considerably
less hubs and showed a steeper decline of the frequency (higher
exponent a of the regression function).
Figure 4 Triangle motifs. The motifs were derived for each triple
of nodes consisting of a hub and two of its neighbors in the
network (n1, n2) which were also mutually connected. In the
integration motif (motif A) all nodes are pair-wise highly co-
regulated. Accordingly, the motif is defined by high correlations
(low distances) for links hub-n1, hub-n2 and n1-n2. In contrast, the
maintenance motif (motif B) consisted of a hub which was not co-
regulated with its neighbors n1 and n2. Counted were triangles
which pairs of hub-nodes (hub-n1 and hub-n2) showed high
correlation in one tissue type and no correlation in the other, while
the correlation of n1-n2 stayed in the same category. Motif C is a
consistent feed-forward loop, taken from the literature [21].
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link, whereas the same operator-receiver pairs for the
tumor did not share any link. We compared the abundance
of this motif with the abundance of its counterpart in
which the cancer cells used at least one common link and
the normal cells did not share any link. We found a signifi-
cantly higher number of our motif in which the normal
cells share a common link (average counts for cancer:
15,333,384, average for normal: 29,618,238, P = 9.54E-06,
Table 3).
Discussion
We investigated network properties of cancer signaling
by looking at co-regulation patterns of genes for differ-
ent cancer types. We analyzed the general regulatory
behavior of correlating gene expression samples of one
tumor type and study, rather than analyzing the regula-
tory behavior of single patients. For this, we calculated a
gene to gene distance metric for all samples (patients)
of normal and cancerous tissues. The networks of the
investigated tumors showed distinctive mechanisms in
the regulation of signal transduction when compared to
normal cells and had shorter path lengths. Luscombe
and co-workers analyzed the dynamics of regulatory net-
works in yeast [11]. In comparison to endogenously
caused changes, they discovered a different topological
adaptation of the network when yeast responded to
environmental changes. For having quick responses,
yeast reacted to environmental changes (nutrition deple-
tion, stress response) by short regulatory cascades. Our
investigated cancer cells showed a similar tendency as
yeast under stress at which fine tuned endogenous
homeostasis is of minor importance. Interestingly, for
yeast, Luscombe et al. discovered a higher frequency of
hubs for stress responses whereas we discovered that
the tumors used hubs less frequently. Cells of normal
sample had a more centralized network to regulate sig-
nals via common nodes and links. This was reflected by
a smaller network, higher frequency of hubs, lower
entropy and a higher number of our signaling motif in
which the number of pathway-pairs with common links
was counted. This makes sense, as fine-tuning and inte-
grating diverse signals need to be coordinately trans-
ferred to the respective transcriptional response which is
substantial for fine grained signaling homeostasis of nor-
mal cells to co-ordinate their signals in accordance to
their cellular community in the tissue. Degenerated
tumor cells do not need this any more. In turn, the
tumors showed a higher connectedness of the whole
network which may strengthen their independency of
exogenic perturbations.
Similar to Cui and co-workers [12], we observed with
our model that cancer specific mutations occur distinc-
tively more often at hubs for signal transduction. Such a
mutation can cause a loss of function. This is beneficial
for the cancer if the protein gets insensitive to
upstream-signals and fires constitutively an oncogenic
signal as e.g. the ABL-BCR fusion protein in chronic
myelogenous leukemia [19]. If the protein acts as a
tumor suppressor, a complete loss of function is benefi-
cial for oncogenesis. In both scenarios, the regulation
for signaling homeostasis of the local network environ-
ment is detached from this mal-functional protein and a
coordinated regulation between the environment and
this protein is not necessary any more. We observed
this by counting distinctively less integration-motifs in
tumors (motif A in Figure 4). Interestingly, tumors seem
to sustain the original signals between the environment.
We observed this by higher counts of the disruption
motif in tumors which reflects the disruption of co-reg-
ulation of the hub, but maintained regulation between
the neighbors of the hubs (motif B in Figure 4). Even
though tumors may exhibit de-regulation of mal-
functional hubs with their neighbors, such a maintained
co-regulation of their neighbors gives evidence that
bypass regulations are still necessary. Ma’ayan and
co-workers observed an accumulation of feedback and
feed-forward loops at such hubs [20] which supports
this idea. Tumors need to maintain the direct signal of
e.g. a feed-forward loop which is necessary for the effect
of the constitutive signal of an oncogenic hub (Figure
4C). Such oncogenic signaling motifs may have implica-
tions to drug therapy. If an oncogenic hub is treated (as
e.g. ABL-BCR with imatinib [19]) resistance can occur
by mutations of the target protein which reduce the affi-
nity of the drug to the target. A combined therapy may
avoid this evolvement by additionally blocking the sig-
naling-maintenance of the neighbors. In addition, we
found that the observed cancer networks showed higher
error tolerance against directed attacks of hub removals.
Hence, some maintenance signals may not only support
cancer mutated hubs but also pave the way for the sig-
naling network to get independent of them, specifically
for proteins of cancer mutated genes with loss-of-func-
tion. It is challenging but highly relevant to shed light
into these effects experimentally with cell lines exhibit-
ing drug resistances at such hubs. We analyzed net-
works based on cohorts of patients and used the
correlation of expression between gene pairs for the
whole cohorts. This approach does not allow the analy-
sis of a single sample and therefore can’t be employed
for diagnosis of a single patient, but rather for the analy-
sis of tumor subgroups. It may be worthwhile develop-
ing distance metrics of gene pairs for single samples
with which the investigated topology features can be
employed supporting diagnosis.
We proposed a novel comparative signaling-motif for
malignant signaling-regulation which sums up our find-
ings (Figure 1). There have been elaborated studies on
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network motifs [21]. Our comparative cancer motif is
different from these motifs in that it shows signaling-
regulation in cancer reflecting less centralized formation.
The comparative cancer motif agrees with our findings
of non-integration (motif A, Figure 4) but signaling-
maintenance (motif B, Figure 4) of proteins with higher
involvement in signal propagation.
Conclusion
We analyzed network models that based on correlation
of gene expression between interacting proteins which
enabled us to track basic principles of signaling by its
regulation. The malignant signaling networks showed
more diverse signaling pathways (average number of
nodes in the networks of tumor: 3324, and normal tis-
sue: 2973, P = 2.3E-03, Figure 2), shorter pathways
(average path-length for cancer: 4.58, and normal: 5.50,
P = 3.82E-05, Figure 2), the networks were less centra-
lized (average clustering-coefficient of cancer: 0.118, and
normal tissue: 0.125, P = 4.20E-04) and less dependent
on hubs (average increase of network-diameter after
hub-removal, for cancer: 1.59, and normal tissue: 1.64, P
= 0.021). The cancer networks indicated signaling main-
tenance and increased error tolerance to punctual
attacks even at hubs which makes cancer treatment at
specific targets challenging.
Methods
The general workflow of our approach is outlined in
Figure 5. To investigate if our network features showed
a statistically significant difference we performed paired
Wilcoxon tests. We set the significance level to P ≤ 0.05
and considered all p-values below this threshold as sta-
tistically significant.
Gene expression analysis
We analyzed twenty different datasets of cancer and
their corresponding normal or reference samples. For
most of the tumors (8 tumors), we analyzed two data-
sets for each cancer type. We used two AML (acute
myeloid leukemia) datasets containing 18 normal and 25
tumor (AML-1) [22] and 4 normal and 52 cancer sam-
ples (AML-2) [23]. The first breast cancer dataset
(breast-1) was obtained from cancer and normal sample
of 43 patients each [24], breast-2 consisted of 143 nor-
mal and 42 cancer samples [25]. We analyzed two cervi-
cal cancer sets, cervical-1 [26] and cervical-2 [27]
comprising data from 8 and 24 normal and 20 and 31
cancer datasets, respectively. Data of esophageal squa-
mous cell carcinomas (ESCC) was obtained from can-
cerous and normal tissue of 53 patients (taken from the
NCBI database Gene Expression Omnibus, accession
code GSE23400). We used a glioma data set containing
23 normal and 153 cancer samples [28]. A head-and-
neck dataset was taken from a study of head-and-neck
squamous carcinoma consisting of data from 22 normal
and cancer samples [29]. We used two lung cancer data-
sets, denoted as “lung-1” and “lung-2”. Lung-1 was taken
from a study by Bhattacharjee and co-workers [30] and
contained data from 17 normal and 13 cancer samples
of adenocarcinoma. Bhattacharjee and co-workers clus-
tered the tumor datasets in their study. To obtain the
most relevant data subsets with the necessary homoge-
neity, we selected their cluster of highly aggressive ade-
nocarcinomas (cluster C2 of their cluster analysis) for
our study. Lung-2 contained gene expression data of
normal sample and adenocarcinoma tumors from 27
patients [31]. We analyzed an oral-tongue-cancer data-
sets comprising of data from 26 normal and 31 cancer
samples (oral-tongue-1 [32]) and 12 and 26 normal and
cancer samples, respectively (oral-tongue-2 [33]).
Figure 5 Workflow of the method. (A) Gene expression data from
normal and tumor samples was mapped onto the respective nodes
of the protein-protein-interaction network. (B) Node distances dxy
were calculated from correlation coefficients of neighboring genes
in the network for normal and tumor samples resulting in one
normal and one tumor network with weighted links. Transcription
factors and receptors were selected from public data repositories
(Gene Ontology and TRANSFAC). (C) Shortest paths were calculated
for all pair-wise combinations of receptors and transcription factors.
Links and nodes that did not appear in any shortest path were
removed and the largest connected component of the remaining
network was used as the representative signaling network. (D)
Network features were calculated for each signaling network and (E)
the results for the networks of tumor and normal samples
compared.
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We analyzed two datasets for pancreas cancer, pancreas-
1 consisting of 39 normal and tumor tissues [34] and
pancreas-2 having 15 normal and 36 cancer samples
[35]. The first prostate cancer dataset (prostate-1) com-
prised of data from 50 normal sample and 52 cancer
samples [36], and the second (prostate-2) consisted of
50 normal and 52 cancer samples (taken from the NCBI
database Gene Expression Omnibus, accession code
GSE17951). The dataset Renal-1 contained 23 normal
renal samples and 69 samples of renal cancer 69 [37]
and renal-2 had 5 normal and 62 cancer samples [38].
For the first renal datasets we selected homogenous
samples by performing hierarchical clustering (Euclidean
distance, complete linkage) yielding sets of nine clus-
tered samples for normal tissue and 10 for cancerous
tissue. We analyzed data from vulva interstitial neoplasia
consisting of 10 normal and 9 cancer samples [39]. All
datasets were stratified by randomly deleting datasets of
the overrepresented class yielding an equal amount of
tumor and normal sample datasets. For breast-1, ESCC,
head-and-neck, lung-2, pancreas-1, and oral-tongue-1,
normal and cancer samples were from the same patients
(which was not the case for the other analyzed datasets).
The data had been obtained using microarrays from
Affymetrix of the following versions: HG-U133A for
AML-1, breast-1, cervical-2, ESCC, lung-2 and renal-1,
HG-U133 Plus 2 for breast-2, cervical-1, glioma, oral-
tongue-2, pancreas-1, pancreas-2, prostate-2, renal-2
and vulva; HG-U95Av2 for AML-2, head-and-neck,
lung-1, oral-tongue-1 and prostate-1. We normalized all
datasets by Variance Stabilization Normalization [40,41].
Network construction
The protein-protein-interaction network was con-
structed using the Human Protein Reference Database
[13,14] (version 9 from April 13th, 2010). Interacting
proteins were represented by their coding genes. The
network was constructed for every gene that could be
mapped to a microarray probe-set using BioMart [42].
Interactions were not taken into account if probe infor-
mation for at least one gene was missing. For a link
between node (gene) x and y, we defined a link-distance
dxy by Pearson’s correlation coefficient rxy from gene












x x y y
x x y y
=
−( ) −( )











dxy xy= −1  (2)
for n samples (patients) and gene expression xi and yi
for gene x and y of sample i, respectively. These dis-
tances were calculated for each dataset of normal and
cancer tissues and used for the networks of the respec-
tive datasets. To equally handle induction and inhibition
events, we used the absolute values of all correlation
coefficients. Correlation values were subtracted from
one to obtain low distances for paths with high correla-
tion. Genes with the molecular function term “receptor
activity” from the definitions of Gene Ontology [43]
were used as receptors in the network. The definitions
of transcription factors were taken from TRANSFAC
[44]. We used Dijkstra’s algorithm [45] for calculating
the shortest paths for every pair of receptors and tran-
scription factors in the normal and tumor networks.
These shortest paths of all receptor-transcription factor
pairs served as the predicted pathways for each dataset
and defined our tumor-specific interaction networks.
Links and nodes that were not used by any shortest
path were removed. The analyses were then performed
on the largest connected component of the interaction
network.
Defining the network features
Path length, link and node frequency, and the signaling
motif are explained in the results. It is to note that link
(and node) frequency is similar to betweenness central-
ity, which is the number of shortest paths going through
the link (and node). While betweenness centrality con-
siders shortest paths between all pairs of nodes, node
and link frequency as defined here, was the number of
shortest paths between pairs of receptors and transcrip-
tion factors. The (average) network diameter has been
described as a measure for error tolerance of a network
against removals of nodes in scale free networks [17]
and was used here in a similar way. The diameters for
the networks were obtained by the average of the short-
est paths of each pair of nodes in the network. The net-
work diameter was calculated for undisturbed (whole)
networks and networks in which the top 10% of the
hubs were removed. The ratio of these values was calcu-
lated to yield the increase of the average network dia-
meter after hub removal. The calculation of the
information content was based on the assumption that
signals enter the network at any receptor with equal
probability within a certain time interval. These signals
are passed by the links of the network to the transcrip-
tion factors via the defined pathways from the receptors,
again with equal probability. We assumed that the sig-
nals vanish from the signaling network after having
entered the corresponding transcription factor at the
end of the path. Signals enter the receptors with a
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certain frequency, resulting in an equal distribution and
therefore we assumed uniform density of the signals in
each pathway. The probability of a signal to pass
through the link of node i and j is then proportional to
the number of pathways passing through this link. With










in which n denotes the number of links and pi the
probability of a signal to be passed through link i. The






in which nlinks is the number of links connecting the
neighbors of node i and k is the number of neighbors.
This feature described how well the neighbors were
mutually connected. If they were fully connected, the
clustering coefficient was one, if they were not con-
nected at all, the clustering coefficient was zero.
Link-frequency distributions
The link-frequency distributions of normal and tumor
cells i followed a power law, i.e. the probability of links
P(f) with link-frequency f was approximately given by
P f f( ) −∝~ (5)
To estimate the exponent a we applied the method
proposed by Newman [46] which determines the expo-
nent of the cumulative distribution avoiding noisy data
at the tail of the original distribution (see tail of the link
frequency distribution in Figure 3). For visualization we
plotted the distribution and the corresponding linear
function with slope a on a log-log scale. The intersec-
tion with the y-axis of the plotted line was calculated
using a least squared fit (see Figure 3 and Additional file
1: Supplemental Figure S2).
Defining and counting the integration and the
maintenance motif
We defined three correlation categories based on inter-
vals of the absolute values of the correlation coefficient |
rxy|: no correlation for the absolute value of correlation
coefficients between zero and 0.3, low correlation for
the absolute value of correlation coefficients between 0.3
and 0.5, and high correlation above 0.5. Hubs of cancer
mutated genes were defined by intersecting the list of
cancer genes from Cui and co-workers (Supplementary
Table S10 in [12]) with the nodes that appeared in both
tissue types (normal and tumor). From this intersection
we selected the top 50 most frequently involved nodes
from the normal and the tumor network resulting in
100 cancer mutated hubs for every cancer dataset. Hubs
that were selected in both tissue types and as such
appeared twice in the union set were used only once.
For each dataset, we collected all triangles in which one
node was such a cancer mutated hub and that appeared
in the normal and in the tumor network ensuring the
comparability of our motif counts. Out of these trian-
gles, we selected triangles having the motifs for integra-
tion (motif A in Figure 4) and maintenance (motif B in
Figure 4). For motif A, we selected triangles in which
the absolute correlations |rxy| between all pairs of nodes
(hub-n1, hub-n2, n1-n2, n1 and n2 are the two other
nodes in the triangle) was high. For motif B, we counted
the abundance of triangles which pairs of hub-nodes
showed high correlation in one tissue type and no corre-
lation in the other, while the correlation of n1-n2 stayed
in the same category (no correlation, low correlation or
high correlation).
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